iNtRON Biotechnology, Inc. (048530.KQ)
KRW 5500.0
(-4.35%)
KRW 5500.0
(-4.35%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -292.11 KRW | -273.48% |
| 2022 | 168.38 KRW | -41.62% |
| 2021 | 288.42 KRW | -39.45% |
| 2020 | 476.32 KRW | 547.54% |
| 2019 | -106.43 KRW | -136.59% |
| 2018 | 290.89 KRW | 199.73% |
| 2017 | -291.68 KRW | -1331.21% |
| 2016 | -20.38 KRW | -138.09% |
| 2015 | 53.50 KRW | 0.0% |
| 2012 | -50.38 KRW | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -11.66 KRW | 89.55% |
| 2024 Q2 | 17.46 KRW | 245.8% |
| 2023 FY | - KRW | -273.48% |
| 2023 Q3 | -78.09 KRW | -40.3% |
| 2023 Q4 | -111.56 KRW | -42.86% |
| 2023 Q2 | -55.66 KRW | -18.93% |
| 2023 Q1 | -46.80 KRW | 56.46% |
| 2022 Q3 | -49.67 KRW | -113.9% |
| 2022 FY | - KRW | -41.62% |
| 2022 Q4 | -107.48 KRW | -116.39% |
| 2022 Q2 | 357.23 KRW | 1103.46% |
| 2022 Q1 | -35.60 KRW | -147.07% |
| 2021 Q1 | 35.74 KRW | -61.75% |
| 2021 FY | - KRW | -39.45% |
| 2021 Q4 | 75.63 KRW | 10.1% |
| 2021 Q2 | 105.27 KRW | 194.54% |
| 2021 Q3 | 68.69 KRW | -34.75% |
| 2020 Q3 | 31.48 KRW | -89.99% |
| 2020 FY | - KRW | 547.54% |
| 2020 Q4 | 93.43 KRW | 196.79% |
| 2020 Q1 | -19.12 KRW | 82.73% |
| 2020 Q2 | 314.39 KRW | 1744.3% |
| 2019 FY | - KRW | -136.59% |
| 2019 Q4 | -110.70 KRW | -20.33% |
| 2019 Q3 | -92.00 KRW | -344.55% |
| 2019 Q2 | 37.62 KRW | 410.14% |
| 2019 Q1 | -12.13 KRW | -103.78% |
| 2018 FY | - KRW | 199.73% |
| 2018 Q2 | 81.44 KRW | 187.62% |
| 2018 Q1 | -92.95 KRW | 79.68% |
| 2018 Q3 | -146.00 KRW | -279.27% |
| 2018 Q4 | 321.14 KRW | 319.96% |
| 2017 Q1 | -2.34 KRW | 95.36% |
| 2017 FY | - KRW | -1331.21% |
| 2017 Q4 | -457.50 KRW | -6938.46% |
| 2017 Q3 | -6.50 KRW | 94.26% |
| 2017 Q2 | -113.24 KRW | -4739.32% |
| 2016 FY | - KRW | -138.09% |
| 2016 Q4 | -50.40 KRW | -320.0% |
| 2016 Q3 | -12.00 KRW | -84.62% |
| 2016 Q2 | -6.50 KRW | -8.33% |
| 2016 Q1 | -6.00 KRW | 0.0% |
| 2015 FY | - KRW | 0.0% |
| 2013 Q3 | 1.54 KRW | 33.91% |
| 2013 Q2 | 1.15 KRW | -85.77% |
| 2013 Q1 | 8.08 KRW | 203.59% |
| 2012 FY | - KRW | 0.0% |
| 2012 Q4 | -7.80 KRW | 36.64% |
| 2012 Q3 | -12.31 KRW | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| HLB Co., Ltd. | -1559.61 KRW | 81.27% |
| BINEX Co., Ltd. | 151.04 KRW | 293.399% |
| Bioneer Corporation | -410.19 KRW | 28.787% |
| Anterogen.Co.,Ltd. | -291.93 KRW | -0.062% |
| MEDIPOST Co., Ltd. | 287.00 KRW | 201.78% |
| CrystalGenomics, Inc. | -661.00 KRW | 55.808% |
| Helixmith Co., Ltd | -1543.76 KRW | 81.078% |
| Chabiotech Co.,Ltd. | -149.80 KRW | -95.0% |
| Medy-Tox Inc. | 1456.65 KRW | 120.054% |
| Peptron, Inc. | -773.61 KRW | 62.241% |
| Amicogen, Inc. | -583.58 KRW | 49.945% |
| Genexine, Inc. | -1652.14 KRW | 82.319% |
| HLB Therapeutics Co.,Ltd. | -32.12 KRW | -809.433% |
| LegoChem Biosciences, Inc. | -2595.00 KRW | 88.743% |
| ALTEOGEN Inc. | -65.27 KRW | -347.541% |
| PharmaResearch Co., Ltd. | 7502.00 KRW | 103.894% |
| SillaJen, Inc. | -179.98 KRW | -62.301% |
| JETEMA, Co., Ltd. | 783.21 KRW | 137.297% |
| OliX Pharmaceuticals,Inc | -1323.81 KRW | 77.934% |
| Genomictree Inc. | -391.00 KRW | 25.292% |
| MedPacto, Inc. | -1664.87 KRW | 82.454% |
| D&D Pharmatech | 409.19 KRW | 171.387% |
| EASY BIO,Inc. | 455.00 KRW | 164.2% |
| GI Innovation, Inc. | -1285.69 KRW | 77.28% |